How long olaparib works depends on the type of cancer being treated and whether the cancer carries specific genetic mutations. In ovarian cancer, where olaparib has shown its strongest results, the drug can keep cancer from progressing for years. In breast, prostate, and pancreatic cancers, the typical window of benefit is shorter, generally measured in months. The drug continues to be taken until it stops working or side effects become unmanageable.
Response Times by Cancer Type
Olaparib’s effectiveness varies significantly across cancer types, largely because of differences in tumor biology and how the drug is used (as a maintenance therapy after chemotherapy or as a standalone treatment).
In ovarian cancer with BRCA mutations, olaparib delivers its most dramatic results. The landmark SOLO-1 trial, which tested olaparib as maintenance therapy after platinum chemotherapy, found that 67% of patients on olaparib were alive at seven years compared to 46.5% on placebo. While the exact median time before cancer progressed wasn’t updated in later analyses, earlier data from the trial showed olaparib delayed progression by years, not months, in this setting.
In metastatic breast cancer with BRCA mutations, the benefit window is narrower. The OlympiAD trial found a median progression-free survival of 7 months with olaparib versus 4.2 months with standard chemotherapy. That’s a meaningful improvement, but the drug’s ability to hold the cancer at bay is measured in months rather than years.
In metastatic prostate cancer with BRCA or ATM mutations, the PROfound trial showed a median of 7.4 months before cancer progressed on olaparib, compared to 3.6 months on standard hormonal treatments. The benefit roughly doubled the time before the disease worsened.
In metastatic pancreatic cancer with BRCA mutations, the POLO trial found olaparib maintained disease control for a median of 7.4 months versus 3.8 months on placebo. Again, approximately double the progression-free window, but still a matter of months for most patients.
How Long You Stay on Treatment
There’s no universal rule for how long olaparib therapy lasts. The FDA-approved label says to continue until the cancer progresses or side effects become intolerable. In practice, the picture is more complicated, and oncologists don’t agree on a single standard.
An international survey of oncologists found that 73% had no institutional guidelines on how long to prescribe the drug. Among those who did, recommendations ranged from 1 year to indefinite treatment. Among those without formal guidelines, about half recommended continuing for five or more years, and nearly half of those recommended indefinite use. A smaller group favored stopping at the 2-year mark. This means your oncologist’s recommendation will likely depend on your specific cancer type, how well the drug is working, and how you’re tolerating it.
The standard dose is two 150 mg tablets taken twice daily (600 mg total per day), with or without food. Doctors typically monitor response through imaging scans roughly every 12 weeks for the first 72 weeks, then every 24 weeks after that, along with regular blood work.
Why Olaparib Eventually Stops Working
Olaparib works by exploiting a weakness in cancer cells that can’t repair their DNA properly, particularly cells with BRCA mutations. The drug blocks a backup DNA repair system, which forces these already-vulnerable cancer cells to accumulate so much genetic damage that they die. This concept, called synthetic lethality, is why BRCA mutation status matters so much for predicting who will benefit.
The most well-understood reason olaparib stops working is that cancer cells find a way to restore their DNA repair ability. They do this through what are called reversion mutations: new genetic changes that essentially undo the original BRCA mutation and allow the repair machinery to function again. Once a cancer cell can fix its DNA normally, the drug’s core strategy no longer applies.
The impact of these reversion mutations is stark. In one study, patients whose tumors had detectable reversion mutations in blood samples before starting treatment had a median progression-free survival of just 1.8 months, compared to 9 months for patients without them. This mechanism isn’t unique to olaparib; it affects the entire class of drugs that work the same way.
Dose Adjustments and Stopping Treatment
Side effects play a real role in determining how long you can stay on olaparib. In the SOLO2 trial of ovarian cancer patients, half of all patients needed at least a temporary pause in treatment due to side effects. About 28% required a lower dose, and 17% had to stop the drug entirely because of adverse events. The most common culprit was anemia, a drop in red blood cells that can cause fatigue, weakness, and shortness of breath.
The reassuring finding from that study is that dose reductions and interruptions did not appear to reduce the drug’s effectiveness. Patients who needed adjustments still saw similar survival benefits to those who stayed on the full dose throughout. This means that if side effects become difficult, your oncologist can lower the dose or pause treatment without necessarily sacrificing the benefit. Some patients cycle through periods of full dosing, reduced dosing, and treatment breaks over months or years.
What Predicts a Longer Response
The single biggest predictor of how long olaparib will work is the genetic profile of the tumor. Cancers with BRCA1 or BRCA2 mutations consistently show the longest and strongest responses. Within that group, patients who had a complete response to prior platinum chemotherapy tend to do better than those with only a partial response, because platinum sensitivity and olaparib sensitivity share overlapping biology.
The absence of reversion mutations at the start of treatment is another strong signal. Patients whose blood tests show no evidence of restored DNA repair genes before beginning olaparib are far more likely to experience a durable response. Some oncologists are beginning to use liquid biopsy tests (blood draws that detect tumor DNA) to look for these markers, though this isn’t yet standard everywhere.
Cancer type also matters independently. Ovarian cancer patients on maintenance olaparib routinely see benefits lasting multiple years, while breast, prostate, and pancreatic cancer patients more commonly see benefits in the 6 to 12 month range. This likely reflects differences in how these cancers grow and how dependent they are on the DNA repair pathways olaparib targets.